Approval · Notice of Compliance 27857 · 2022
RYBREVANT: Notice of Compliance 27857
Issued March 30, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
Issued with conditions (NOC/c): the company must confirm the benefit in further studies.
- Notice number
- 27857
- Date
- March 30, 2022
- Company
- Janssen Inc.Toronto, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- With conditions
- Yes (NOC/c)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RYBREVANT | 02526182 | Marketed |
Medicinal ingredients
- AMIVANTAMAB 350 MG per 7ML